To analyze the prevalence and types of BRCA1/2 mutations in Vietnamese patients with breast, ovarian, prostate, and pancreatic cancers using next-generation sequencing.
Approach:
Study Design: Retrospective cohort study conducted in collaboration with Vinmec Healthcare System and several National Oncology Hospitals in Vietnam.
Patient Selection: Patients diagnosed with triple-negative breast cancer, high-grade serous ovarian cancer, prostate cancer, or pancreatic cancer were selected based on NCCN Guidelines.
Sample Collection: Genomic DNA was primarily extracted from peripheral blood samples, with FFPE tumor tissue specimens used when necessary.
Key Findings:
Germline mutations in BRCA1/2 are significant risk factors for hereditary cancers.
BRCA1/2 mutations are implicated in various malignancies beyond breast and ovarian cancers.
There is a lack of comprehensive data on BRCA1/2 mutations in the Vietnamese population.
Interpretation:
The study aims to fill the knowledge gap regarding BRCA1/2 mutations in Vietnamese patients, which is crucial for effective genetic counseling and targeted therapy.
Limitations:
Limited existing data on BRCA1/2 mutations in Vietnam.
Previous studies primarily focused on Western and East Asian populations.
Conclusion:
The study provides insights into the genetic landscape of BRCA1/2 mutations in various cancer types in Vietnam, which may inform personalized oncology care.
Breast cancer screening has traditionally been organized around two principal variables: when mammography should begin and how frequently it should be performed.
Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.
Researchers develop targeted lipoplex platform that generates CAR T and NK cells directly within tumors, improving survival in preclinical breast cancer models
